PNC Financial Services Group’s Aardvark Therapeutics AARD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.81K Sell
344
-5
-1% -$31 ﹤0.01% 4861
2026
Q2
$2.01K Buy
349
+321
+1,146% +$1.5K ﹤0.01% 4678
2026
Q1
$106 Buy
+28
New +$290 ﹤0.01% 5093
2025
Q4
– Sell
-140
Closed -$1.86K – 5342
2025
Q3
$1.86K Buy
+140
New +$1.58K ﹤0.01% 4518

Other funds holding AARD

PNC Financial Services Group's AARD Position: Q3 2026 in Review

PNC Financial Services Group reduced its Aardvark Therapeutics (AARD) stake by 1.4% in Q3 2026, selling an estimated $31 and leaving 344 shares worth $1.81K. The position accounts for ﹤0.01% of the portfolio, ranked #4861.

PNC Financial Services Group first reported a position in AARD in Q3 2025 and has held it in 4 quarters since. The position peaked at $2.01K in Q2 2026. 76 funds tracked by Wall St. Rank hold AARD as of Q3 2026.

  • PNC Financial Services Group held 344 shares of Aardvark Therapeutics worth $1.81K as of Q3 2026.
  • PNC Financial Services Group sold 5 Aardvark Therapeutics shares in Q3 2026, an estimated $31.
  • Aardvark Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q3 2026, its #4861 holding.
  • PNC Financial Services Group first reported a position in Aardvark Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • PNC Financial Services Group's Aardvark Therapeutics position peaked at $2.01K in Q2 2026.
  • 76 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q3 2026.

Based on PNC Financial Services Group's 13F filing for Q3 2026, filed 6 Nov 2026.